Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Semester 2 > Non-operative Management of Lung Cancer > Flashcards

Non-operative Management of Lung Cancer Flashcards

1
Q

What type of lung cancer makes up 85% of lung cancer?

A

Non-small cell cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the types of non-small cell lung cancer?

A

Squamous (30%)

Adenocarcinoma (55%)

Large cell undifferentiated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What type of cancer makes up about 15% of ung cancers?

A

Small cell cancer - extremely aggressive - doubles in size every 29 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Where do you normally find squamous and adenocarcinoma cancers?

A

Squamous - usually more central (usually male, usually smokers)

Adenocarcinoma - more peripheral, usualy in woman

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What does stage 4 mean?

A

Distant metastases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the percentage of non-small cell cancer is operable?

A

maximum of 25%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are all the therapeutic options for cancer?

A

Surgery

Radiotherapy (radical/curative or palliative)

Chemotherapy

Combination

Targetted therapies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What determines the therapeutic options?

A

Tumour type, stage, ECOG performance status, patient wishes and options, aims of therapy (curative or palliative)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

NSCLC: What are the scores available for the ECOG performance status measurement?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the average 5 year survival for non-small cell lung cancer?

A

Around 40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is meant by adjuvant therapy?

A

When the cancer has appeared to all have been removed – but it is post operative treatment to ensure all cancer has been removed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Is adjuvant therapy helpful in stage 1 and 2 non-small cell lung cancer?

A

Detrimental - but some possible benefits if mediastinal nodes (N2 or involved margins)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

NSCLC: When does preoperative chemotherapy demonstrate significant survival advantage?

A

Stage 3 Non small cell lung cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What percent of Non small cell lung cancer patients have adbvanced disease?

A

80% of all patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the dose for stage 3 Non small cell lung cancer radiotherapy?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the survival rate for stage 3 non small cel lung cancer?

A

20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is survival of stage 3 non small cell cancer for patients treated with ChemoRT?

A

About 27%

18
Q

What is treatment for stage 4 NSCLC?

A

Incurable

Palliation essential

RT to primary tumour to releive symptoms (~70% symptom benefit)

(—Chemo gives equal symptomatic benefit AND survival advantage)

—Median survival now >12 months with chemo alone

19
Q

What is the average number of cycles of chemo for stage 3 NSCLC?

A

—3 as good as 6 cycles of chemo (4 is average in UK)

20
Q

NSCLC: What should be considered in the case of Painful bone metastases and Brain mets?

A

Painful bone mets - radiotherapy

Brain mets – resection

21
Q

NSCLC: What are the features of Bone pain from mets?

A

Occurs in any site

Often worse at night

Potential for pathological fracture

Need for palliative radiotherapy

22
Q

NSCLC: What is pemetrexed used for?

A

Maintainance chemotherapy

23
Q

What can drugs target in NSCLC?

A

Drugs that can target the driver mutation in ADENOCARCINOMA

24
Q

NSCLC: Give examples of Driver mutations for NSCLC

A

EGFR mutation

ALK translocation

BRAF mutation

ROS alteration

25
Q

NSCLC: Who are targetted drugs used by?

A

Patients who are unfit for chemotherapy

26
Q

NSCLC: What is the concept for Tyrosine Kinase Inhibitors?

A

Blocks Tyrosine Kinase which is a membrane receptor protein - This stops the formation of a protein causing the tumour to grow

27
Q

What drugs are Tyrosine Kinase Inhibitors?

A

Erlotinib, gefitinib, afatinib

28
Q

Whar us Tarceva?

A

Tyrosine Kinase inhibitor used to treat EGFR mutations

29
Q

What is the function of Nivolumab?

A

Blocks the binding of PD-1 to PD-L1 and PD-L2

This potentiates the activity of lymphocytes by preventing them from being activated

30
Q

What percentage of lung cancer patients have small cell lung cancer?

A

Roughly 15%

31
Q

What is different between the presentation of small cell lung cancer and NSCLC?

A

Presentation identical but secretory syndromes are present.

e.g SIADH (The syndrome of inappropriate antidiuretic hormone (ADH) secretion)

Low sodium - confusion

ACTH (Adrenocorticotropic hormone - Its principal effects are increased production and release of cortisol by the cortex of the adrenal gland) - causing Cushings - hypersecretion of ACTH by the pituitary gland

32
Q

What are the two classifications of Small cell lung cancer severity?

A

Limited Disease - Staged to one hemithorax

Extensive disease - more advanced disease

33
Q

How do you treat SCLC of limited disease?

A

Chemotherapy

Combination of drugs including cisplastin and etoposide

Early thoracic radiotherapy is better

Prophylactic cranial radiation

Only resect about 1 lung cancer per year for those with small cell lung cancer – SURGERY IS NOT THE TREATMENT, chemotherapy dominated treatment

34
Q

In SCLC is there any benefit from any of the following?

High Dose chemo?

Alternating Chemo?

Maintainance Chemo?

Chemo ‘on demand’?

Maintainance interferon?

A

NO

35
Q

What is response rate of limited disease treatment?

A

90%

Complete remission is 60%

36
Q

What is median survival of limited disease SCLC with and without treatment?

A

With - 8 months

Without - 16 months

37
Q

What is the rate of two year survival with SCLC in limited disease?

A

25%

38
Q

What is the treatment for SCLC in extensive disease?

A

4 cycles of combination chemotherapy

Percutaneous coronary intervention (PCI) recommended - non-surgical procedure used to treat narrowing (stenosis) of the coronary arteries of the heart found in coronary artery disease

Single fraction RT to palliate if not fit for chemo

If brain Mets - RT and steroids

39
Q

What is the percentage of patients that are diagnosed too late to cure?

A

80%

40
Q
A

Semester 2 (150 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions